Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Addiction Recovery Medications' 'Stigma' Needs To Be Eliminated, Gottlieb Says

Executive Summary

US FDA commissioner tells House committee that culture changes – and label changes – are among the actions the agency is pursuing to address the opioid crisis.

Advertisement

Related Content

Braeburn's Buprenorphine Candidate Faces Safety Gauntlet At US FDA Panel
Opioid Packaging Changes Might Deter Abuse – And Generic Competition
Buprenorphine Injectable Opioid Abuse Treatment: Will REMS Prevent Misuse?
Declaring Opioid Emergency, Trump Touts FDA Actions, NIH-Industry Partnerships
Opioid Hearing: Senators Want Speed, But Agency Heads Stress Time, Effort
Biopharma Largely Avoids Partisan Bloodbath At US Pricing Hearing

Topics

Advertisement
UsernamePublicRestriction

Register

PS121842

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel